Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)

Clicks: 4
ID: 298573
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #468 of 543 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 543 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
Reference Key
openalex_W3019235900 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, Valéry Lavergne, Lindsey R. Baden, Vincent Chi‐Chung Cheng, Kathryn M. Edwards, Rajesh T. Gandhi, William J. Muller, John C. O’Horo, Shmuel Shoham, M. Hassan Murad, Reem A. Mustafa, Shahnaz Sultan, Yngve Falck–Ytter
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2020
DOI
10.1093/cid/ciaa478
URL
https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa478/33659841/ciaa478.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.